Clinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, ...
Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using ...
Biomerica, Inc. announced that the American Medical Association's CPT editorial panel has granted a Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, which personalizes the ...
inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS) Research Finds Patients Following a Personalized Diet Therapy Created with inFoods ® IBS, ...
The inFoods ® IBS test is a novel, non-invasive diagnostic that identifies patient-specific IBS trigger foods that may be contributing to IBS symptoms such as bloating, abdominal pain, diarrhea, and ...
Biomerica applies for a PLA code to enhance patient access to its inFoods IBS diagnostic test for personalized IBS management. Biomerica, Inc. has submitted an application to the American Medical ...
An elimination diet guided by a novel irritable bowel syndrome (IBS)–specific immunoglobulin G (IgG) assay reduced abdominal pain in a greater proportion of patients with IBS than a sham elimination ...
inFoods IBS showed improvement in API similar to, and in some cases better than, current IBS drugs in the market NEWPORT BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), ...
Commonwealth Diagnostics International will officially re-launch IBSchek, the first clinically validated blood test for diarrhea-predominant and mixed-type irritable bowel syndrome, at Digestive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results